The Covid-19 pandemic triggered a significant rise in Spac investments in the healthtech sector. While Spacs offer opportunities for healthtech companies, the road to a de-Spac process can be complex and perilous.
See if you get the FT for free as a student (http://ft.com/schoolsarefree) or start a £1 trial: https://subs.ft.com/spa3_trial?segmentId=3d4ba81b-96bb-cef0-9ece-29efd6ef2132.
► Check out our Community tab for more stories on the economy.
► Listen to our podcasts: https://www.ft.com/podcasts
► Follow us on Instagram: https://www.instagram.com/financialtimes’